Nurse Practitioner - Therapy for Multi-Drug Resistant Strep in CAP
Levofloxacin (Levaquin) is now approved by the FDA to treat multidrug-resistant strains of Streptococcus pneumoniae in community-acquired pneumonia (CAP), in the forms of tablets, injection, and in 5% dextrose (Levaquin Injection). Levofloxacin is a product of Johnson & Johnson.nLevofloxacin is indicated for dosage once daily.The safety and efficacy of levofloxacin have not been established in pregnant women and nursing mothers, pediatrie patients, or adolescents. It is contraindicated in people hypersensitive to levofloxacin and quinolone antimicrobials. The drug should be discontinued at the first appearance of a skin rash or other sign of hypersensitivity.
Related Results
Levaquin approvalLevaquin doseNew indication for LevaquinOral solution levaquin approvedLevaquin tablets and oral solution
Consult full product labeling for prescribing precautions.
Copyright Springhouse Corporation Oct 2004
Provided by ProQuest Information and Learning Company. All rights Reserved
